1 / 17

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). Presented By Martin Schlumberger at 2014 ASCO Annual Meeting. Disclosures.

jarah
Download Presentation

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  3. Study Rationale Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  4. Study 303: Study Schema Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  5. Patient Characteristics Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  6. Primary Endpoint:<br />Kaplan-Meier Estimate of PFS Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  7. PFS by Previous VEGF-Targeted Therapy Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  8. PFS Subgroup Analyses Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  9. Response Rates Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  10. Best Tumor Response Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  11. Overall Survival, ITT population Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  12. Study Medication Exposure Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  13. Treatment-emergent Adverse Events (TEAEs) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  14. Most Frequent Treatment-related Adverse Events (> 20%) Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  15. TEAEs of Special Interest Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  16. Conclusions Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

  17. Slide 17 Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

More Related